Brokerages Set Cryoport, Inc. (NASDAQ:CYRX) PT at $18.63

Cryoport, Inc. (NASDAQ:CYRX) has been assigned a consensus recommendation of “Hold” from the seven ratings firms that are currently covering the company, Marketbeat Ratings reports. Five analysts have rated the stock with a hold rating and two have issued a buy rating on the company. The average 12-month target price among analysts that have issued a report on the stock in the last year is $18.63.

Several equities analysts have issued reports on the stock. Stephens reaffirmed an “equal weight” rating and issued a $17.00 price target on shares of Cryoport in a report on Wednesday, March 13th. Jefferies Financial Group assumed coverage on shares of Cryoport in a report on Thursday, April 4th. They issued a “buy” rating and a $21.00 price target on the stock. Needham & Company LLC cut their price target on shares of Cryoport from $19.00 to $18.00 and set a “buy” rating on the stock in a report on Wednesday, March 13th. Finally, UBS Group boosted their price objective on shares of Cryoport from $14.50 to $17.00 and gave the company a “neutral” rating in a report on Friday, March 15th.

Insider Buying and Selling at Cryoport

In other Cryoport news, Director Ramkumar Mandalam sold 3,217 shares of the company’s stock in a transaction on Friday, March 15th. The shares were sold at an average price of $14.68, for a total value of $47,225.56. Following the sale, the director now directly owns 43,187 shares of the company’s stock, valued at $633,985.16. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. In other Cryoport news, CEO Jerrell Shelton sold 57,039 shares of the company’s stock in a transaction dated Friday, March 15th. The shares were sold at an average price of $15.30, for a total value of $872,696.70. Following the completion of the transaction, the chief executive officer now owns 634,352 shares in the company, valued at $9,705,585.60. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Ramkumar Mandalam sold 3,217 shares of the company’s stock in a transaction dated Friday, March 15th. The stock was sold at an average price of $14.68, for a total transaction of $47,225.56. Following the completion of the transaction, the director now owns 43,187 shares of the company’s stock, valued at approximately $633,985.16. The disclosure for this sale can be found here. Over the last three months, insiders have sold 73,940 shares of company stock valued at $1,147,538. 10.10% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of CYRX. Natixis Investment Managers International raised its position in shares of Cryoport by 61.5% during the 4th quarter. Natixis Investment Managers International now owns 4,536 shares of the company’s stock worth $70,000 after purchasing an additional 1,727 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank grew its stake in Cryoport by 13.9% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 11,462 shares of the company’s stock valued at $157,000 after acquiring an additional 1,395 shares in the last quarter. WINTON GROUP Ltd purchased a new stake in Cryoport during the 3rd quarter valued at about $163,000. Pathstone Family Office LLC purchased a new stake in Cryoport during the 3rd quarter valued at about $165,000. Finally, Quantbot Technologies LP grew its stake in Cryoport by 109.0% during the 3rd quarter. Quantbot Technologies LP now owns 12,838 shares of the company’s stock valued at $176,000 after acquiring an additional 6,694 shares in the last quarter. Institutional investors and hedge funds own 92.90% of the company’s stock.

Cryoport Stock Performance

Shares of NASDAQ:CYRX opened at $16.81 on Friday. The company has a market capitalization of $826.38 million, a price-to-earnings ratio of -7.64 and a beta of 1.60. Cryoport has a 52 week low of $9.00 and a 52 week high of $24.17. The company has a quick ratio of 11.16, a current ratio of 11.73 and a debt-to-equity ratio of 0.82. The firm has a 50 day moving average of $16.90 and a 200 day moving average of $15.06.

Cryoport (NASDAQ:CYRX) last issued its quarterly earnings data on Tuesday, March 12th. The company reported ($0.51) EPS for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.19). Cryoport had a negative return on equity of 11.86% and a negative net margin of 42.69%. The business had revenue of $57.26 million during the quarter, compared to the consensus estimate of $58.27 million. On average, sell-side analysts predict that Cryoport will post -1.31 earnings per share for the current fiscal year.

About Cryoport

Cryoport, Inc provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services.